Psyence Biomedical Valuation

Is PBM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PBM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PBM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PBM's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PBM?

Key metric: As PBM is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for PBM. This is calculated by dividing PBM's market cap by their current book value.
What is PBM's PB Ratio?
PB Ratio	-0.08x
Book	-US$10.97m
Market Cap	US$844.85k

PBM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-3.8x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does PBM's PB Ratio compare to its peers?

The above table shows the PB ratio for PBM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	0.2x
HSTO.Q Histogen	0.2x	n/a	US$918.4k
SQZB SQZ Biotechnologies	0.4x	n/a	US$678.3k
VYNT Vyant Bio	0.3x	n/a	US$1.1m
ZVSA ZyVersa Therapeutics	0.2x	n/a	US$1.2m
PBM Psyence Biomedical	n/a	n/a	US$844.8k

Price-To-Book vs Peers: PBM has negative equity and a Price-To-Book Ratio (-0.1x) compared to the peer average (0.2x).

Price to Book Ratio vs Industry

How does PBM's PB Ratio compare vs other companies in the US Biotechs Industry?

61 Companies	Price / Book	Estimated Growth	Market Cap
GRAL GRAIL	0.2x	35.7%	US$497.29m
AMRN Amarin	0.4x	-7.7%	US$205.67m
IMAB I-Mab	0.4x	1.8%	US$84.69m
ACET Adicet Bio	0.4x	6.7%	US$78.03m

61 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: PBM has negative equity and a Price-To-Book Ratio (-0.1x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is PBM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PBM PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-0.08x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PBM's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Collegium Pharmaceutical

US$954.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.22

-9.2%

14.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.25

-10.5%

7.7%

Teva Pharmaceutical Industries

US$18.6b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.49

-5.1%

74.5%